August 13, 2021 -- BioAffinity Technologies is highlighting results from a research study using a flow cytometry method it has developed.
Published in the Journal of Visualized Experiments, the results show that the company's CyPath technology is an "efficient and effective" method to analyze sputum using flow cytometry, allowing for the development of diagnostic tests for lung cancer and other lung diseases, according to the company.
CyPath is a platform technology used to diagnose cancer, and the company's first product is CyPath Lung, a noninvasive test for the early detection of lung cancer that allows patients to collect their sputum sample at home.